MCID: OVR012
MIFTS: 52

Ovarian Serous Cystadenocarcinoma

Categories: Cancer diseases, Endocrine diseases, Reproductive diseases

Aliases & Classifications for Ovarian Serous Cystadenocarcinoma

MalaCards integrated aliases for Ovarian Serous Cystadenocarcinoma:

Name: Ovarian Serous Cystadenocarcinoma 12 56 6 15 17 74
Serous Cystadenoma 12 17
Cystadenoma, Serous 74
Cystadenoma Serous 56

Classifications:



External Ids:

Disease Ontology 12 DOID:5746
NCIt 51 C7978

Summaries for Ovarian Serous Cystadenocarcinoma

Disease Ontology : 12 An ovary serous adenocarcinoma that has material basis in glandular epithelium, in which cystic accumulations of retained secretions are formed.

MalaCards based summary : Ovarian Serous Cystadenocarcinoma, also known as serous cystadenoma, is related to adenocarcinoma and thyroid cancer. An important gene associated with Ovarian Serous Cystadenocarcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Innate Immune System and Class I MHC mediated antigen processing and presentation. The drugs Paclitaxel and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include pancreas, ovary and brain, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Related Diseases for Ovarian Serous Cystadenocarcinoma

Diseases related to Ovarian Serous Cystadenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 129)
# Related Disease Score Top Affiliating Genes
1 adenocarcinoma 30.8 BRAF HRAS PIK3CA TP53
2 thyroid cancer 30.2 BRAF HRAS NRAS PIK3CA TP53
3 lung cancer susceptibility 3 30.2 BRAF HRAS NRAS PIK3CA TP53
4 serous cystadenocarcinoma 30.1 FBXW7 HRAS MUC16 PGR PIK3CA PPP2R1A
5 cystadenocarcinoma 30.1 FBXW7 HRAS MUC16 PGR PIK3CA PPP2R1A
6 endometrial cancer 29.6 BCL2 BRAF HRAS MUC16 PGR PIK3CA
7 ovarian cancer 29.0 BCL2 BRAF FSHR MUC16 PGR PIK3CA
8 pancreatic serous cystadenoma 12.7
9 serous or mucinous cystadenoma of childhood 11.3
10 cystadenoma 11.1
11 giant congenital nevus 10.5 HRAS NRAS
12 adult hepatocellular carcinoma 10.5 PIK3CA TP53
13 nevus of ota 10.5 BRAF TP53
14 rare adenocarcinoma of the breast 10.4 PIK3CA TP53
15 anal squamous cell carcinoma 10.4 FBXW7 PIK3CA TP53
16 malignant spiradenoma 10.4 PIK3CA TP53
17 apocrine adenoma 10.4 HRAS PIK3CA
18 endometrium carcinoma in situ 10.4 PGR TP53
19 adenoma 10.4
20 epithelial-myoepithelial carcinoma 10.4 FBXW7 HRAS TP53
21 acneiform dermatitis 10.4 HRAS NRAS PIK3CA
22 erdheim-chester disease 10.4 BRAF NRAS PIK3CA
23 ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3 10.4 PIK3CA PPP2R1A TP53
24 prostate adenoid cystic carcinoma 10.4 HRAS LRRC56 PIK3CA
25 brain stem glioma 10.4 BRAF PIK3CA TP53
26 nevus, epidermal 10.4 HRAS NRAS PIK3CA
27 benign struma ovarii 10.4 HRAS NRAS
28 ovarian cancer 1 10.3 PIK3CA TP53 ZNF217
29 anaplastic thyroid cancer 10.3 BRAF PIK3CA TP53
30 skin melanoma 10.3 BRAF NRAS TP53
31 bladder squamous cell carcinoma 10.3 BRAF TP53
32 pulmonic stenosis 10.3 BRAF HRAS LRRC56
33 respiratory system cancer 10.3 HRAS PIK3CA TP53
34 colorectal adenocarcinoma 10.3 BRAF HRAS TP53
35 hyperplastic polyposis syndrome 10.3 BRAF TP53
36 uterine corpus serous adenocarcinoma 10.3 FBXW7 PIK3CA PPP2R1A TP53
37 meningeal melanomatosis 10.3 B2M HRAS NRAS TP53
38 testicular germ cell tumor 10.3 BRAF HRAS TP53
39 estrogen-receptor positive breast cancer 10.3 PGR PIK3CA TP53
40 ovarian cystadenocarcinoma 10.3 HRAS UBE4A ZNF217
41 adrenocortical carcinoma, hereditary 10.3 BRAF NRAS PIK3CA TP53
42 uterine anomalies 10.3 PGR PIK3CA TP53
43 histiocytic sarcoma 10.3 BCL2 BRAF
44 intestinal disease 10.3 HRAS PIK3CA TP53
45 suppression of tumorigenicity 12 10.3 BRAF HRAS PIK3CA TP53
46 leukemia, chronic lymphocytic 2 10.3 BRAF HRAS NRAS TP53
47 spitz nevus 10.3 BRAF HRAS LRRC56 TP53
48 ovary adenocarcinoma 10.3 HRAS PIK3CA TP53 ZNF217
49 schimmelpenning-feuerstein-mims syndrome 10.3 HRAS NRAS
50 thyroid cancer, nonmedullary, 2 10.3 BRAF HRAS NRAS PIK3CA

Graphical network of the top 20 diseases related to Ovarian Serous Cystadenocarcinoma:



Diseases related to Ovarian Serous Cystadenocarcinoma

Symptoms & Phenotypes for Ovarian Serous Cystadenocarcinoma

GenomeRNAi Phenotypes related to Ovarian Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

27 (show all 15)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-10 9.93 USP2
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-119 9.93 USP14
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-134 9.93 BCL2
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-139 9.93 BCL2
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 9.93 USP2
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-165 9.93 BCL2
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-179 9.93 BCL2
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-200 9.93 USP2
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 9.93 USP2
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-28 9.93 HRAS
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-59 9.93 BCL2
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 9.93 BCL2 HRAS USP14 USP2
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-87 9.93 BCL2 HRAS
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-95 9.93 HRAS USP14
15 Increased cell death HMECs cells GR00103-A-0 9.1 FBXW7 PGR PIK3CA PPP2R1A TP53 ZNF217

MGI Mouse Phenotypes related to Ovarian Serous Cystadenocarcinoma:

47 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.34 B2M BCL2 BRAF FBXW7 FSHR NANOG
2 behavior/neurological MP:0005386 10.3 BCL2 BRAF FSHR HRAS NRAS PGR
3 cardiovascular system MP:0005385 10.29 B2M BCL2 BRAF FBXW7 FSHR HRAS
4 endocrine/exocrine gland MP:0005379 10.25 B2M BCL2 BRAF FBXW7 FSHR HRAS
5 homeostasis/metabolism MP:0005376 10.21 B2M BCL2 BRAF FBXW7 FSHR HRAS
6 growth/size/body region MP:0005378 10.18 B2M BCL2 BRAF FBXW7 FSHR HRAS
7 embryo MP:0005380 10.11 BCL2 BRAF FBXW7 NANOG NRAS PGR
8 integument MP:0010771 10.1 B2M BCL2 BRAF FBXW7 FSHR HRAS
9 mortality/aging MP:0010768 10.1 B2M BCL2 BRAF FBXW7 FSHR HRAS
10 digestive/alimentary MP:0005381 10.08 B2M BCL2 BRAF FBXW7 HRAS NRAS
11 neoplasm MP:0002006 9.93 B2M BCL2 BRAF FBXW7 FSHR HRAS
12 no phenotypic analysis MP:0003012 9.5 HRAS NANOG NRAS PGR PIK3CA TP53
13 reproductive system MP:0005389 9.32 B2M BCL2 BRAF FSHR PATL2 PGR

Drugs & Therapeutics for Ovarian Serous Cystadenocarcinoma

Drugs for Ovarian Serous Cystadenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 117)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
2
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 38904 10339178 498142
3
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 441203 84093 2767
4
Bevacizumab Approved, Investigational Phase 3,Phase 1 216974-75-3
5
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 6055-19-2, 50-18-0 2907
6
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
7
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Not Applicable 59-30-3 6037
8 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
9 Antimitotic Agents Phase 3,Phase 2,Phase 1
10 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
11 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
12 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
13 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
14 Angiogenesis Modulating Agents Phase 3,Phase 1
15 Angiogenesis Inhibitors Phase 3,Phase 1
16 Antineoplastic Agents, Immunological Phase 3,Phase 1
17 Mitogens Phase 3,Phase 1
18 Antibodies Phase 3,Phase 1
19 Endothelial Growth Factors Phase 3,Phase 1
20 Antibodies, Monoclonal Phase 3,Phase 1
21 Immunoglobulin G Phase 3,Phase 1
22 Immunoglobulins Phase 3,Phase 1
23 Antirheumatic Agents Phase 3,Phase 2,Phase 1
24 Alkylating Agents Phase 3,Phase 2,Phase 1
25 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
26 Analgesics Phase 3,Phase 1
27 Peripheral Nervous System Agents Phase 3,Phase 1,Not Applicable
28 Trace Elements Phase 3,Not Applicable
29 Vitamins Phase 3,Not Applicable
30 Nutrients Phase 3,Not Applicable
31 Vitamin B Complex Phase 3,Not Applicable
32 Folate Phase 3,Not Applicable
33 Vitamin B9 Phase 3,Not Applicable
34 Micronutrients Phase 3,Not Applicable
35
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
36
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
37
Sirolimus Approved, Investigational Phase 2 53123-88-9 46835353 6436030 5284616
38
Letrozole Approved, Investigational Phase 2 112809-51-5 3902
39
Doxorubicin Approved, Investigational Phase 2,Phase 1 23214-92-8 31703
40
Belinostat Approved, Investigational Phase 2 866323-14-0
41
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
42
Lenograstim Approved, Investigational Phase 2,Phase 1 135968-09-1
43
Topotecan Approved, Investigational Phase 2,Phase 1 123948-87-8, 119413-54-6 60700
44
Docetaxel Approved, Investigational Phase 1, Phase 2,Phase 2 114977-28-5 148124
45
Metformin Approved Phase 2,Phase 1 657-24-9 14219 4091
46
Gemcitabine Approved Phase 2 95058-81-4 60750
47
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
48
Doxil Approved June 1999 Phase 2,Phase 1 31703
49
MK-1775 Investigational Phase 2 501-36-0, 955365-80-7 24856436 445154
50
Emodepside Investigational, Vet_approved Phase 2 155030-63-0

Interventional clinical trials:

(show top 50) (show all 66)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of Antiadhesive Barrier GUARDIX-FL for Women After Laparoscopic Cystectomy Unknown status NCT02097446 Phase 3
2 Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer Completed NCT00002568 Phase 3 cisplatin;paclitaxel
3 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
4 Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer Completed NCT00002717 Phase 3 cisplatin;paclitaxel
5 Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer Completed NCT00003322 Phase 3 cisplatin;paclitaxel
6 Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer Completed NCT00003644 Phase 3 carboplatin;paclitaxel
7 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00951496 Phase 3 Carboplatin;Carboplatin;Cisplatin;Paclitaxel;Paclitaxel
8 Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer Terminated NCT00003880 Phase 2, Phase 3 carboplatin;paclitaxel
9 Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer Terminated NCT00002819 Phase 3 carboplatin;cyclophosphamide;mitoxantrone hydrochloride;paclitaxel
10 Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy Withdrawn NCT01492920 Phase 3
11 Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer Unknown status NCT02283658 Phase 2 Everolimus;Letrozole
12 VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Unknown status NCT01666444 Phase 2 pegylated liposomal doxorubicin (PLD);VTX-2337;Placebo
13 Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer Unknown status NCT00017303 Phase 2 carboplatin;oglufanide disodium;paclitaxel
14 Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin Completed NCT00993616 Phase 2 belinostat;carboplatin
15 A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00939809 Phase 2
16 Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy Completed NCT00466960 Phase 2 paclitaxel albumin-stabilized nanoparticle formulation
17 Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma Completed NCT00059787 Phase 2 paclitaxel;carboplatin;erlotinib
18 S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer Completed NCT00008138 Phase 2 carboplatin;paclitaxel
19 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00003944 Phase 2 carboplatin;cyclophosphamide;paclitaxel;topotecan hydrochloride
20 TLK286 in Treating Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00022347 Phase 2 canfosfamide hydrochloride
21 Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Completed NCT00217529 Phase 1, Phase 2 carboplatin;docetaxel;erlotinib hydrochloride
22 Laparoscopic Staging in Patients With Ovarian, Fallopian Tube, or Other Primary Abdominal Cancers Completed NCT00002538 Phase 2
23 Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02122185 Phase 2 metformin hydrochloride;placebo;Chemotherapy
24 Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT02101775 Phase 2 Adavosertib;Gemcitabine Hydrochloride
25 Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer Terminated NCT00004221 Phase 2 Carboplatin;Cyclophosphamide;Paclitaxel;Topotecan Hydrochloride
26 Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Terminated NCT00331422 Phase 2 carboplatin;paclitaxel
27 Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer Terminated NCT00354601 Phase 2 capecitabine;docetaxel
28 Toremifene in Treating Patients With Ovarian Cancer Withdrawn NCT00003865 Phase 2 toremifene
29 EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT01489371 Phase 1 Pegylated Liposomal Doxorubicin Hydrochloride
30 Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Completed NCT01459380 Phase 1 Carboplatin;Pegylated Liposomal Doxorubicin Hydrochloride;Veliparib
31 TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer Completed NCT01294293 Phase 1 TLR8 Agonist VTX-2337;Pegylated Liposomal Doxorubicin Hydrochloride;Paclitaxel
32 Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT01074411 Phase 1 Bortezomib;Carboplatin
33 Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00814086 Phase 1 Paclitaxel;Cisplatin
34 Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer) Completed NCT00085358 Phase 1 carboplatin;paclitaxel;docetaxel
35 Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00079430 Phase 1 paclitaxel;carboplatin
36 Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer Completed NCT00002913 Phase 1 paclitaxel;cisplatin;topotecan hydrochloride
37 Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer Completed NCT00060359 Phase 1 Carboplatin;Paclitaxel Poliglumex
38 Liposomal Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00006235 Phase 1 carboplatin;pegylated liposomal doxorubicin hydrochloride
39 Combination Chemotherapy, Bone Marrow Transplantation, and Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer Completed NCT00002600 Phase 1 carboplatin;cyclophosphamide
40 Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer Completed NCT00003967 Phase 1 etoposide;topotecan hydrochloride
41 Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer Completed NCT00408590 Phase 1
42 Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer Completed NCT00005026 Phase 1 carboplatin;paclitaxel;topotecan hydrochloride
43 Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors Completed NCT00066651 Phase 1
44 Melphalan and Thiotepa Followed by Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer in Complete Remission Completed NCT00002977 Phase 1 melphalan;thiotepa
45 RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma Completed NCT00101972 Phase 1
46 Gene Therapy in Treating Patients With Cancer Completed NCT00004178 Phase 1
47 Immunotoxin Therapy in Treating Patients With Advanced Cancer Completed NCT00006981 Phase 1
48 Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer Completed NCT00003385 Phase 1 carboplatin;paclitaxel;pegylated liposomal doxorubicin hydrochloride
49 TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors Active, not recruiting NCT02142803 Phase 1 Sapanisertib
50 Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer Active, not recruiting NCT00357448 Phase 1

Search NIH Clinical Center for Ovarian Serous Cystadenocarcinoma

Genetic Tests for Ovarian Serous Cystadenocarcinoma

Anatomical Context for Ovarian Serous Cystadenocarcinoma

MalaCards organs/tissues related to Ovarian Serous Cystadenocarcinoma:

42
Pancreas, Ovary, Brain, Liver, Bone, Endothelial, Bone Marrow

Publications for Ovarian Serous Cystadenocarcinoma

Articles related to Ovarian Serous Cystadenocarcinoma:

(show top 50) (show all 93)
# Title Authors Year
1
Giant serous cystadenoma of the pancreas appearing sonographically as a remote pararenal mass. ( 30907433 )
2019
2
Two protein-coding genes act as a novel clinical signature to predict prognosis in patients with ovarian serous cystadenocarcinoma. ( 29456732 )
2018
3
A Network Pharmacology-Based Analysis of Multi-Target, Multi-Pathway, Multi-Compound Treatment for Ovarian Serous Cystadenocarcinoma. ( 30097905 )
2018
4
Gastric metastasis of ovarian serous cystadenocarcinoma. ( 30233254 )
2018
5
Bilateral Breast and Axillary Lymph Nodes Metastases of an Ovarian Serous Cystadenocarcinoma. ( 30287996 )
2018
6
A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma. ( 30446011 )
2018
7
The honeycomb pattern of pancreatic serous cystadenoma. ( 30288583 )
2018
8
Atypical Solid Serous Cystadenoma of the Pancreas. ( 30454515 )
2018
9
Serous cystadenoma of pancreas: A clinicopathologic experience of 23 cases from a major tertiary care center. ( 30542522 )
2018
10
Expression of Yes-associated proteinA 1 and its clinical significance in ovarian serous cystadenocarcinoma. ( 28339095 )
2017
11
DNA methylation-regulated microRNA pathways in ovarian serous cystadenocarcinoma: A meta-analysis. ( 27746113 )
2016
12
Estimation of Prognostic Marker Genes by Public Microarray Data in Patients with Ovarian Serous Cystadenocarcinoma. ( 27189279 )
2016
13
A Five-Gene Expression Signature Predicts Clinical Outcome of Ovarian Serous Cystadenocarcinoma. ( 27478834 )
2016
14
Single nucleotide polymorphisms in glutathione S-transferase P1 and M1 genes and overall survival of patients with ovarian serous cystadenocarcinoma treated with chemotherapy. ( 27073511 )
2016
15
Tumor-to-tumor metastasis: report of two cases of renal cell carcinoma metastasizing to microcystic serous cystadenoma of the pancreas. ( 24873824 )
2015
16
Serous cystadenoma of pancreas: imaging diagnosis. ( 26591957 )
2015
17
Unilocular macrocystic serous cystadenoma of the pancreas--atypical features: a case report. ( 24461471 )
2014
18
Tumour-to-tumour metastasis of lung adenocarcinoma to ovarian serous cystadenoma. ( 24724546 )
2014
19
An unusual case of a borderline Brenner tumor associated with bilateral serous cystadenoma and endometrial carcinoma. ( 24791367 )
2014
20
Ovarian serous cystadenocarcinoma metastasising to the breast. ( 23445161 )
2013
21
Largest Serous Cystadenoma in the first Trimester treated Laparoscopically: A Case Report. ( 28861184 )
2012
22
Nanog is highly expressed in ovarian serous cystadenocarcinoma and correlated with clinical stage and pathological grade. ( 21266826 )
2010
23
A case of serous cystadenoma of the pancreas with a central stellate scar detected on contrast-enhanced ultrasound with perflubutane. ( 26192303 )
2009
24
Activation of the PI3K/AKT pathway mediates FSH-stimulated VEGF expression in ovarian serous cystadenocarcinoma. ( 18574502 )
2008
25
Plasma cell leukemia with ovarian serous cystadenocarcinoma. ( 17883177 )
2007
26
[Differential expression of USP2, USP14 and UBE4A between ovarian serous cystadenocarcinoma and adjacent normal tissues]. ( 17553343 )
2007
27
[Oncogene ZNF217 amplification on chromosome 20 q in ovarian serous cystadenocarcinoma and its clinical implications]. ( 16793610 )
2006
28
[ZNF217 gene was detected in ovarian serous cystadenocarcinoma by fluorescence in situ hybridization]. ( 17160949 )
2006
29
Serous cystadenoma of the pancreas in a child. ( 14523873 )
2003
30
Serous cystadenoma of the pancreas associated with obstructive jaundice. ( 12768395 )
2003
31
Discrimination of unilocular macrocystic serous cystadenoma from pancreatic pseudocyst and mucinous cystadenoma with CT: initial observations. ( 12954892 )
2003
32
Serous cystadenoma of the pancreas associated with pancreas divisum. ( 12203086 )
2002
33
Peritoneal melanosis combined with serous cystadenoma of the ovary: a case report and literature review. ( 12685549 )
2002
34
Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: the effect on survival. ( 11201519 )
2001
35
Immunohistochemical localization of aromatase and apoptosis-associated proteins in ovarian serous cystadenocarcinoma arising from ovarian endometriosis. ( 11516810 )
2001
36
Macrocystic serous cystadenoma of the pancreas: case report. ( 11116364 )
2001
37
Macrocystic type of serous cystadenoma with a communication between the cyst and pancreatic duct. ( 11446898 )
2001
38
Torsion of benign serous cystadenoma of the fallopian tube: a challenge in differential diagnosis of abdominal pain in women during their childbearing years--a case report. ( 11517866 )
2001
39
Serous cystadenoma of the pancreas with papillary features: a diagnostic pitfall on fine-needle aspiration biopsy. ( 11735697 )
2001
40
Microcystic serous cystadenoma mimicking malignancy in pancreas. ( 11837486 )
2001
41
Successful treatment of an advanced ovarian serous cystadenocarcinoma in pregnancy with cisplatin, adriamycin and cyclophosphamide (CAP) regimen. Case report. ( 10968352 )
2000
42
Pancreatic serous cystadenoma associated with islet cell tumour. ( 10721327 )
2000
43
Macrocystic serous cystadenoma of the pancreas: importance of co-existent tiny cysts depicted by EUS. ( 10864357 )
2000
44
A small serous cystadenoma of the pancreas: endoscopic ultrasonographic findings. ( 10881941 )
2000
45
Macrocystic serous cystadenoma of the pancreas. ( 10982598 )
2000
46
High concentrations of inhibin A and inhibin B in ovarian serous cystadenoma: relationship with oestradiol and nitric oxide metabolites. ( 11101690 )
2000
47
A discrepant finding between magnetic resonance imaging and other imaging modalities suggests a microcystic serous cystadenoma of the pancreas. ( 11373064 )
2000
48
Macrocystic serous cystadenoma of the pancreas: CT and endosonographic features. ( 9933678 )
1999
49
Estrogen receptor alpha (ER-alpha) and beta (ER-beta) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: down-regulation of ER-beta in neoplastic tissues. ( 9506768 )
1998
50
Serous cystadenoma of the pancreas with invasive growth: benign or malignant? ( 9772066 )
1998

Variations for Ovarian Serous Cystadenocarcinoma

ClinVar genetic disease variations for Ovarian Serous Cystadenocarcinoma:

6 (show top 50) (show all 453)
# Gene Variation Type Significance SNP ID Assembly Location
1 TP53 NM_001126115.1(TP53): c.443G> T (p.Arg148Ile) single nucleotide variant Uncertain significance rs121912660 GRCh38 Chromosome 17, 7673781: 7673781
2 TP53 NM_001126115.1(TP53): c.443G> T (p.Arg148Ile) single nucleotide variant Uncertain significance rs121912660 GRCh37 Chromosome 17, 7577099: 7577099
3 TP53 NM_001126115.1(TP53): c.401G> A (p.Gly134Glu) single nucleotide variant Conflicting interpretations of pathogenicity rs193920774 GRCh38 Chromosome 17, 7673823: 7673823
4 TP53 NM_001126115.1(TP53): c.401G> A (p.Gly134Glu) single nucleotide variant Conflicting interpretations of pathogenicity rs193920774 GRCh37 Chromosome 17, 7577141: 7577141
5 BRAF NM_004333.4(BRAF): c.1742A> G (p.Asn581Ser) single nucleotide variant Likely pathogenic rs121913370 GRCh37 Chromosome 7, 140453193: 140453193
6 BRAF NM_004333.4(BRAF): c.1742A> G (p.Asn581Ser) single nucleotide variant Likely pathogenic rs121913370 GRCh38 Chromosome 7, 140753393: 140753393
7 TP53 NM_000546.5(TP53): c.722C> G (p.Ser241Cys) single nucleotide variant Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
8 TP53 NM_000546.5(TP53): c.722C> G (p.Ser241Cys) single nucleotide variant Likely pathogenic rs28934573 GRCh38 Chromosome 17, 7674241: 7674241
9 TP53 NM_000546.5(TP53): c.842A> T (p.Asp281Val) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh38 Chromosome 17, 7673778: 7673778
10 TP53 NM_000546.5(TP53): c.842A> T (p.Asp281Val) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh37 Chromosome 17, 7577096: 7577096
11 TP53 NM_000546.5(TP53): c.713G> A (p.Cys238Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs730882005 GRCh38 Chromosome 17, 7674250: 7674250
12 TP53 NM_000546.5(TP53): c.713G> A (p.Cys238Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs730882005 GRCh37 Chromosome 17, 7577568: 7577568
13 TP53 NM_000546.5(TP53): c.709A> G (p.Met237Val) single nucleotide variant Uncertain significance rs730882004 GRCh38 Chromosome 17, 7674254: 7674254
14 TP53 NM_000546.5(TP53): c.709A> G (p.Met237Val) single nucleotide variant Uncertain significance rs730882004 GRCh37 Chromosome 17, 7577572: 7577572
15 TP53 NM_000546.5(TP53): c.646G> A (p.Val216Met) single nucleotide variant Conflicting interpretations of pathogenicity rs730882025 GRCh38 Chromosome 17, 7674885: 7674885
16 TP53 NM_000546.5(TP53): c.646G> A (p.Val216Met) single nucleotide variant Conflicting interpretations of pathogenicity rs730882025 GRCh37 Chromosome 17, 7578203: 7578203
17 TP53 NM_000546.5(TP53): c.856G> A (p.Glu286Lys) single nucleotide variant Pathogenic/Likely pathogenic rs786201059 GRCh38 Chromosome 17, 7673764: 7673764
18 TP53 NM_000546.5(TP53): c.856G> A (p.Glu286Lys) single nucleotide variant Pathogenic/Likely pathogenic rs786201059 GRCh37 Chromosome 17, 7577082: 7577082
19 TP53 NM_000546.5(TP53): c.814G> A (p.Val272Met) single nucleotide variant Uncertain significance rs121912657 GRCh37 Chromosome 17, 7577124: 7577124
20 TP53 NM_000546.5(TP53): c.814G> A (p.Val272Met) single nucleotide variant Uncertain significance rs121912657 GRCh38 Chromosome 17, 7673806: 7673806
21 TP53 NM_000546.5(TP53): c.578A> T (p.His193Leu) single nucleotide variant Conflicting interpretations of pathogenicity rs786201838 GRCh37 Chromosome 17, 7578271: 7578271
22 TP53 NM_000546.5(TP53): c.578A> T (p.His193Leu) single nucleotide variant Conflicting interpretations of pathogenicity rs786201838 GRCh38 Chromosome 17, 7674953: 7674953
23 TP53 NM_000546.5(TP53): c.578A> G (p.His193Arg) single nucleotide variant Likely pathogenic rs786201838 GRCh37 Chromosome 17, 7578271: 7578271
24 TP53 NM_000546.5(TP53): c.578A> G (p.His193Arg) single nucleotide variant Likely pathogenic rs786201838 GRCh38 Chromosome 17, 7674953: 7674953
25 TP53 NM_000546.5(TP53): c.527G> A (p.Cys176Tyr) single nucleotide variant Conflicting interpretations of pathogenicity rs786202962 GRCh37 Chromosome 17, 7578403: 7578403
26 TP53 NM_000546.5(TP53): c.527G> A (p.Cys176Tyr) single nucleotide variant Conflicting interpretations of pathogenicity rs786202962 GRCh38 Chromosome 17, 7675085: 7675085
27 TP53 NM_000546.5(TP53): c.487T> G (p.Tyr163Asp) single nucleotide variant Likely pathogenic rs786203436 GRCh37 Chromosome 17, 7578443: 7578443
28 TP53 NM_000546.5(TP53): c.487T> G (p.Tyr163Asp) single nucleotide variant Likely pathogenic rs786203436 GRCh38 Chromosome 17, 7675125: 7675125
29 TP53 NM_000546.5(TP53): c.431A> C (p.Gln144Pro) single nucleotide variant Uncertain significance rs786203071 GRCh37 Chromosome 17, 7578499: 7578499
30 TP53 NM_000546.5(TP53): c.431A> C (p.Gln144Pro) single nucleotide variant Uncertain significance rs786203071 GRCh38 Chromosome 17, 7675181: 7675181
31 TP53 NM_000546.5(TP53): c.374C> T (p.Thr125Met) single nucleotide variant Conflicting interpretations of pathogenicity rs786201057 GRCh38 Chromosome 17, 7675995: 7675995
32 TP53 NM_000546.5(TP53): c.374C> T (p.Thr125Met) single nucleotide variant Conflicting interpretations of pathogenicity rs786201057 GRCh37 Chromosome 17, 7579313: 7579313
33 TP53 NM_000546.5(TP53): c.824G> A (p.Cys275Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs863224451 GRCh38 Chromosome 17, 7673796: 7673796
34 TP53 NM_000546.5(TP53): c.824G> A (p.Cys275Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs863224451 GRCh37 Chromosome 17, 7577114: 7577114
35 TP53 NM_000546.5(TP53): c.584T> C (p.Ile195Thr) single nucleotide variant Pathogenic rs760043106 GRCh38 Chromosome 17, 7674947: 7674947
36 TP53 NM_000546.5(TP53): c.584T> C (p.Ile195Thr) single nucleotide variant Pathogenic rs760043106 GRCh37 Chromosome 17, 7578265: 7578265
37 TP53 NM_000546.5(TP53): c.374C> A (p.Thr125Lys) single nucleotide variant Uncertain significance rs786201057 GRCh38 Chromosome 17, 7675995: 7675995
38 TP53 NM_000546.5(TP53): c.374C> A (p.Thr125Lys) single nucleotide variant Uncertain significance rs786201057 GRCh37 Chromosome 17, 7579313: 7579313
39 PIK3CA NM_006218.3(PIK3CA): c.1635G> T (p.Glu545Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913275 GRCh37 Chromosome 3, 178936093: 178936093
40 PIK3CA NM_006218.3(PIK3CA): c.1635G> T (p.Glu545Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913275 GRCh38 Chromosome 3, 179218305: 179218305
41 TP53 NM_000546.5(TP53): c.700T> G (p.Tyr234Asp) single nucleotide variant Conflicting interpretations of pathogenicity rs864622237 GRCh38 Chromosome 17, 7674263: 7674263
42 TP53 NM_000546.5(TP53): c.700T> G (p.Tyr234Asp) single nucleotide variant Conflicting interpretations of pathogenicity rs864622237 GRCh37 Chromosome 17, 7577581: 7577581
43 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
44 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh38 Chromosome 17, 7674221: 7674221
45 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
46 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 GRCh38 Chromosome 17, 7674230: 7674230
47 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 GRCh37 Chromosome 17, 7577547: 7577547
48 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 GRCh38 Chromosome 17, 7674229: 7674229
49 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
50 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh38 Chromosome 17, 7674220: 7674220

Expression for Ovarian Serous Cystadenocarcinoma

Search GEO for disease gene expression data for Ovarian Serous Cystadenocarcinoma.

Pathways for Ovarian Serous Cystadenocarcinoma

Pathways related to Ovarian Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 70)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.06 B2M BCL2 BRAF FBXW7 HRAS MUC16
2
Show member pathways
13.48 B2M FBXW7 HRAS NRAS PIK3CA PPP2R1A
3
Show member pathways
13.27 B2M BCL2 BRAF HRAS NANOG NRAS
4
Show member pathways
13.05 BCL2 HRAS NRAS PGR PIK3CA PPP2R1A
5
Show member pathways
13.01 BCL2 HRAS NRAS PIK3CA PPP2R1A TP53
6
Show member pathways
12.98 B2M BCL2 HRAS NRAS PIK3CA TP53
7
Show member pathways
12.89 BCL2 BRAF HRAS NRAS PIK3CA TP53
8 12.85 BCL2 BRAF HRAS NRAS PIK3CA TP53
9
Show member pathways
12.83 BCL2 HRAS NRAS PIK3CA TP53
10
Show member pathways
12.74 HRAS NRAS PIK3CA PPP2R1A TP53
11
Show member pathways
12.68 BCL2 BRAF HRAS NRAS PIK3CA TP53
12
Show member pathways
12.68 BCL2 BRAF HRAS NRAS PIK3CA TP53
13
Show member pathways
12.66 BCL2 BRAF HRAS NRAS PPP2R1A TP53
14
Show member pathways
12.6 BRAF HRAS NRAS PIK3CA TP53
15
Show member pathways
12.58 BCL2 BRAF HRAS NRAS PGR PIK3CA
16 12.54 BCL2 HRAS NRAS PIK3CA TP53
17
Show member pathways
12.52 BRAF HRAS NRAS PIK3CA TP53
18
Show member pathways
12.49 BCL2 HRAS NRAS PIK3CA
19
Show member pathways
12.47 BCL2 HRAS NRAS PIK3CA TP53 YAP1
20
Show member pathways
12.45 HRAS PIK3CA PPP2R1A TP53
21
Show member pathways
12.44 BCL2 HRAS NRAS PIK3CA TP53
22
Show member pathways
12.43 BCL2 BRAF HRAS NRAS
23
Show member pathways
12.4 BRAF HRAS NRAS PIK3CA
24 12.37 HRAS NRAS PIK3CA TP53
25
Show member pathways
12.37 BRAF PGR PIK3CA PPP2R1A
26
Show member pathways
12.35 BCL2 BRAF HRAS NRAS
27 12.31 HRAS NRAS PIK3CA TP53
28
Show member pathways
12.27 BRAF HRAS NRAS TP53
29
Show member pathways
12.24 BRAF HRAS NRAS PIK3CA PPP2R1A
30
Show member pathways
12.22 BCL2 HRAS NRAS PIK3CA
31 12.2 HRAS NRAS PIK3CA TP53
32
Show member pathways
12.17 BRAF HRAS NRAS TP53
33
Show member pathways
12.16 HRAS NRAS PIK3CA TP53
34 12.12 HRAS NANOG NRAS PIK3CA
35
Show member pathways
12.11 BRAF HRAS NRAS PIK3CA
36
Show member pathways
12.1 BCL2 HRAS NRAS PIK3CA PPP2R1A
37 12.09 BCL2 HRAS NRAS PIK3CA TP53
38 12.07 BCL2 HRAS NRAS PIK3CA
39
Show member pathways
12.04 BCL2 HRAS NRAS PPP2R1A
40
Show member pathways
12.01 BRAF HRAS NRAS PIK3CA TP53
41 12 HRAS NRAS PIK3CA TP53
42 11.98 BRAF HRAS NRAS PPP2R1A
43
Show member pathways
11.98 BCL2 BRAF HRAS NRAS PIK3CA TP53
44 11.97 BRAF HRAS NRAS TP53
45 11.94 BCL2 BRAF HRAS TP53
46 11.93 BRAF PIK3CA PPP2R1A
47 11.9 BCL2 HRAS NRAS PIK3CA
48 11.88 BCL2 PIK3CA TP53
49
Show member pathways
11.87 HRAS NRAS PIK3CA
50
Show member pathways
11.79 BRAF HRAS NRAS PIK3CA

GO Terms for Ovarian Serous Cystadenocarcinoma

Biological processes related to Ovarian Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.85 BCL2 NANOG PIK3CA TP53
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.81 BRAF FBXW7 FSHR HRAS
3 regulation of gene expression GO:0010468 9.78 BCL2 NANOG PIK3CA YAP1
4 cell proliferation GO:0008283 9.72 BCL2 HRAS NANOG TP53 YAP1
5 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.7 BCL2 BRAF PIK3CA
6 Ras protein signal transduction GO:0007265 9.63 HRAS NRAS TP53
7 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.58 HRAS MUC16 NRAS
8 positive regulation of intracellular estrogen receptor signaling pathway GO:0033148 9.54 FSHR YAP1
9 regulation of mitochondrial membrane permeability GO:0046902 9.49 BCL2 TP53
10 negative regulation of neuron apoptotic process GO:0043524 9.46 BCL2 BRAF HRAS PIK3CA
11 progesterone receptor signaling pathway GO:0050847 9.43 PGR YAP1
12 somatic stem cell population maintenance GO:0035019 9.43 BRAF NANOG YAP1
13 circadian behavior GO:0048512 9.37 TP53 USP2
14 cell aging GO:0007569 9.13 BCL2 HRAS TP53
15 cellular response to gamma radiation GO:0071480 8.8 HRAS TP53 YAP1

Molecular functions related to Ovarian Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein heterodimerization activity GO:0046982 9.65 BCL2 BRAF PPP2R1A TP53 YAP1
2 ubiquitin protein ligase binding GO:0031625 9.62 BCL2 FBXW7 TP53 USP2
3 protein binding GO:0005515 9.6 B2M BCL2 BRAF FBXW7 FSHR HRAS
4 identical protein binding GO:0042802 9.5 B2M BCL2 BRAF FBXW7 PGR TP53
5 transcription regulatory region DNA binding GO:0044212 9.46 NANOG TP53 YAP1 ZNF217

Sources for Ovarian Serous Cystadenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....